Biotech, Small Pharma IPO Market Frozen For At Least Next Year, VCs Say – Bio Korea
This article was originally published in PharmAsia News
Executive Summary
OSONG, South Korea - The worldwide market for biotech and other pharmaceutical companies seeking funds through initial public offers is closed for at least a year and other sources of money are becoming scarce as well, venture capital firms said during the annual Bio Korea conference in Osong, South Korea
You may also be interested in...
Novartis Korea Venture Fund, OrbiMed Co-lead Series A Financing For South Korean mAb Developer PharmAbcine
SEOUL - Novartis Korea Venture Fund, OrbiMed's Caduceus Asia Partners and local vaccine producer Green Cross plan to invest $6 million in the next three years to support development of PharmAbcine's fully human monoclonal antibodies to treat cancer and inflammatory diseases
Novartis Korea Venture Fund, OrbiMed Co-lead Series A Financing For South Korean mAb Developer PharmAbcine
SEOUL - Novartis Korea Venture Fund, OrbiMed's Caduceus Asia Partners and local vaccine producer Green Cross plan to invest $6 million in the next three years to support development of PharmAbcine's fully human monoclonal antibodies to treat cancer and inflammatory diseases
Novartis Korea Venture Fund, OrbiMed Co-lead Series A Financing For South Korean mAb Developer PharmAbcine
The financing is a first where a Korean start-up was able to attract an international syndicate of this stature, OrbiMed Caduceus Asia Partners Managing Director Chang said